|Articles|November 11, 2007
Highlights from Day 2 of the AAO Congress
New roles for the femtosecond discussed. Subretinal implant disappoints. Genentech defends its actions relating to Avastin decision. Glaucoma pipeline looks very healthy, and much more.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
3
Port Delivery System Therapies in Retinal Vascular Diseases
4
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
5


















